NASDAQ: ACXP
Acurx Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for ACXP

Based on 2 analysts offering 12 month price targets for Acurx Pharmaceuticals Inc

Min Forecast
$31.00+376.19%
Avg Forecast
$95.50+1,366.97%
Max Forecast
$160.00+2,357.76%

Should I buy or sell ACXP stock?

Based on 2 analysts offering ratings for Acurx Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ACXP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ACXP as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ACXP stock forecasts and price targets.

ACXP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-30
lockedlocked$00.00+00.00%2025-05-15

1 of 1

Forecast return on equity

Is ACXP forecast to generate an efficient return?

Forecast return on assets

Is ACXP forecast to generate an efficient return on assets?

ACXP revenue forecast

What is ACXP's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$87.9M
Avg 3 year Forecast
$114.7M

ACXP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACXP$6.51$95.50+1,366.97%Buy
LYRA$6.37$16.00+151.18%Hold
IMNN$4.85$255.00+5,157.73%Strong Buy
APM$1.49N/AN/A
XTLB$1.23N/AN/A

Acurx Pharmaceuticals Stock Forecast FAQ

Is Acurx Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ACXP) stock is to Buy ACXP stock.

Out of 2 analysts, 0 (0%) are recommending ACXP as a Strong Buy, 2 (100%) are recommending ACXP as a Buy, 0 (0%) are recommending ACXP as a Hold, 0 (0%) are recommending ACXP as a Sell, and 0 (0%) are recommending ACXP as a Strong Sell.

If you're new to stock investing, here's how to buy Acurx Pharmaceuticals stock.

What is ACXP's revenue growth forecast for 2025-2031?

(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Acurx Pharmaceuticals's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast ACXP's revenue for 2025 to be $0, with the lowest ACXP revenue forecast at $0, and the highest ACXP revenue forecast at $0. On average, 3 Wall Street analysts forecast ACXP's revenue for 2030 to be $139,274,781, with the lowest ACXP revenue forecast at $133,813,647, and the highest ACXP revenue forecast at $143,371,425.

In 2031, ACXP is forecast to generate $181,773,693 in revenue, with the lowest revenue forecast at $174,642,205 and the highest revenue forecast at $187,114,384.

What is ACXP's forecast return on assets (ROA) for 2025-2025?

(NASDAQ: ACXP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -100.54%.

What is ACXP's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ACXP price target, the average ACXP price target is $95.50, with the highest ACXP stock price forecast at $160.00 and the lowest ACXP stock price forecast at $31.00.

On average, Wall Street analysts predict that Acurx Pharmaceuticals's share price could reach $95.50 by Sep 30, 2026. The average Acurx Pharmaceuticals stock price prediction forecasts a potential upside of 1,366.97% from the current ACXP share price of $6.51.

What is ACXP's forecast return on equity (ROE) for 2025-2025?

(NASDAQ: ACXP) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.